Diego-González, L; Crecente-Campo, J; Paul, MJ; Singh, M; Reljic, R; Alonso, MJ; González-Fernández, Á; Simón-Vázquez, R
(2020)
Design of Polymeric Nanocapsules for Intranasal Vaccination against Mycobacterium Tuberculosis: Influence of the Polymeric Shell and Antigen Positioning.
Pharmaceutics, 12 (6).
p. 489.
ISSN 1999-4923
https://doi.org/10.3390/pharmaceutics12060489
SGUL Authors: Paul, Mathew John
Abstract
Tuberculosis (TB) is the leading cause of death from a single infectious microorganism and Bacillus Calmette Guerin (BCG), the only authorized vaccine, does not confer protection against pulmonary TB. Based on the hypothesis that mucosal protection could help to prevent the infection at the site of entrance, the objective of this work was to develop an intranasal vaccine against Mycobacterium tuberculosis (Mtb), the microorganism that causes TB. Our approach consisted of the use of polymeric nanocapsules (NCs) with an oily core and a polymer shell made of chitosan (CS) or inulin/polyarginine (INU/pArg). The immunostimulant Imiquimod, a Toll-like receptor-7 (TLR-7) agonist, was encapsulated in the oily core and a fusion protein, formed by two antigens of Mtb, was absorbed either onto the NC surface (CS:Ag and INU:pArg:Ag) or between two polymer layers (INU:Ag:pArg) in order to assess the influence of the antigen positioning on the immune response. Although CS NCs were more immunostimulant than the INU/pArg NCs in vitro, the in vivo experiments showed that INU:pArg:Ag NCs were the only prototype inducing an adequate immunoglobulin A (IgA) response. Moreover, a previous immunization with BCG increased the immune response for CS NCs but, conversely, decreased for INU/pArg NCs. Further optimization of the antigen and the vaccination regime could provide an efficacious vaccine, using the INU:pArg:Ag NC prototype as nanocarrier.
Item Type: |
Article
|
Additional Information: |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open accessarticle distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
Keywords: |
10 kDa culture filtrate protein (CFP-10), 6 kDa early secretory antigenic target (ESAT-6), Imiquimod, Toll-like receptor-7 (TLR-7), antibodies, complement system, cytokines, reactive oxygen species (ROS), vaccination |
SGUL Research Institute / Research Centre: |
Academic Structure > Infection and Immunity Research Institute (INII) |
Journal or Publication Title: |
Pharmaceutics |
ISSN: |
1999-4923 |
Language: |
eng |
Dates: |
Date | Event |
---|
28 May 2020 | Published | 26 May 2020 | Accepted |
|
Publisher License: |
Creative Commons: Attribution 4.0 |
Projects: |
Project ID | Funder | Funder ID |
---|
643558 | Horizon 2020 Framework Programme | UNSPECIFIED | ED431C 2016/041 | Xunta de Galicia | UNSPECIFIED | ED431C 2017/09 | Xunta de Galicia | UNSPECIFIED | ED431G2019/06 | European Regional Development Fund | UNSPECIFIED | ED481A-2018/294 | Xunta de Galicia | UNSPECIFIED | ED481D-2017/017 | Xunta de Galicia | UNSPECIFIED |
|
PubMed ID: |
32481601 |
![](http://static.pubmed.gov/portal/portal3rc.fcgi/2745237/img/27842) |
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/112155 |
Publisher's version: |
https://doi.org/10.3390/pharmaceutics12060489 |
Statistics
Item downloaded times since 15 Jul 2020.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |